These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17569311)

  • 1. [Combination of ACEI and ARB therapy for heart failure].
    Nishikimi T; Matsuoka H
    Nihon Rinsho; 2007 May; 65 Suppl 5():140-4. PubMed ID: 17569311
    [No Abstract]   [Full Text] [Related]  

  • 2. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combination therapy with ARB for heart failure].
    Sakata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():123-7. PubMed ID: 17569310
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract]   [Full Text] [Related]  

  • 6. Underuse of evidence-based therapies.
    Hlatky MA
    Circulation; 2004 Aug; 110(6):644-5. PubMed ID: 15302805
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination therapy of beta blockers for heart failure].
    Watanabe M; Hirata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():129-33. PubMed ID: 17571376
    [No Abstract]   [Full Text] [Related]  

  • 12. RAS blockers: Does sex matter? Re: Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure - A population study: Marie Hudson et al. European Journal of Heart Failure 9 (2007) 602-609.
    Strauss MH; Hall A
    Eur J Heart Fail; 2007 Sep; 9(9):963-4; author reply 964. PubMed ID: 17669685
    [No Abstract]   [Full Text] [Related]  

  • 13. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of combination angiotensin-converting enzyme and angiotensin receptor blocker therapy on heart failure mortality and morbidity.
    Kapoor JR
    Am J Cardiol; 2008 Mar; 101(5):744-5. PubMed ID: 18308033
    [No Abstract]   [Full Text] [Related]  

  • 15. ACEI and ARB may also benefit CHF through immune system modulation (down-regulation of immune system).
    Fett JD
    Int J Cardiol; 2005 Aug; 103(1):107. PubMed ID: 16061132
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Triple/quadruple therapy in heart failure: integrating scientific evidence with clinical reasoning].
    Sinagra G; Sabbadini G; Zecchin M; Di Lenarda A
    G Ital Cardiol (Rome); 2007 Sep; 8(9):559-67. PubMed ID: 17972425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment and renal function in patients with chronic kidney disease.
    Renke M; Rutkowski P; Tylicki L; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2010 Jun; 11(2):146-7. PubMed ID: 20223790
    [No Abstract]   [Full Text] [Related]  

  • 19. All clinical trials are not created equal: The dilemma of HEAAL.
    Hauptman PJ
    Eur J Heart Fail; 2008 Sep; 10(9):817-8. PubMed ID: 18774334
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Zhang Y; Zhang P; Mu Y; Gao M; Wang JR; Wang Y; Su LQ; Hou YL
    Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.